Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Amy Vega Takes A Novel Approach To Nursing Education
When you think of continuing education for nursing, you may imagine medical textbooks, complicated graphs and loads of acronyms. Well, Amy Glenn Vega hopes to transform continuing education by taking nursing lessons and crafting them into steamy page-turners nurses can read while cozying up next to the fireplace in their favorite comfy chairs.
generic viagra online
Alzheimer's Disease Is The Focus Of TBSI Annual Neuroscience Symposium
Brazos Valley residents, neuroscience researchers, and interested clinicians will each have opportunities to hear from internationally recognized researchers on the topic of aging and Alzheimer"s Disease during the Texas Brain and Spine Institute"s Third Annual Neuroscience Symposium on September 3 and 4. This year"s symposium will consist of an evening of public presentations aimed at helping local residents, Alzheimer"s patients, and their family members better understand early signs of the disease and ways to reduce your risk. The Friday afternoon session will feature a clinical presentation for health providers and researchers.
News of the day
Teens Are Exposed To Tobacco Content On Social Networking Sites
When teens surf the Internet, are they exposed to tobacco content or imagery? The study, "Exposure to Tobacco on the Internet: Content Analysis of Adolescents" Internet Use," tracked the Web pages viewed by 346 teens between the ages of 14 and 17 years. During a one-month period of data collection, these adolescents viewed 1.2 million Web pages. Of those pages, 0.72 percent contained tobacco or smoking content. Pro-tobacco content was found on 1,916 pages, anti-tobacco content on 1,572 pages, and complex and/or unclear content on 5,055 pages. Most of the tobacco-related content seen by teens was found on social networking sites. MySpace in particular represented 53 percent of the pages on which tobacco content was found. Previous studies have found a link between exposure to tobacco content in traditional media and adolescent smoking. The authors caution that as more communication occurs online in social networking sites, this may also impact adolescent smoking.
Mental Health

Merck Serono Initiates Phase III Study Of Stimuvax In Breast Cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the initiation of its global Phase III clinical study of the therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. The STRIDEa study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study. The STRIDE study will be supervised by an expert Steering Committee and is sponsored by Merck Serono, which is leading the development of Stimuvax. STRIDE will enroll more than 900 patients with advanced breast cancer at an estimated 180 sites in over 30 countries - within North America, Europe, Asia and Australia; the Principal Investigator is Dr Lawrence Shulman, Chief Medical Officer and Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, USA. "Advanced-stage breast cancer remains an ultimately fatal and challenging disease and we urgently need new treatment options," said Dr Shulman. "If the results from the Phase III STRIDE study prove positive, this could make a difference for patients with hormone receptor-positive metastatic breast cancer." Stimuvax is an investigational therapeutic cancer vaccine designed to stimulate the body"s immune system to identify and target cancer cells that express MUC1, an antigen commonly expressed in breast cancer as well as in other common cancer types such as non-small cell lung cancer (NSCLC), multiple myeloma, and colorectal, prostate and ovarian cancers.1 "The initiation of the STRIDE study is an enormous step forward in clinical breast cancer research and represents our continued commitment to developing Stimuvax within a robust clinical trial program across several cancer types. We are very excited that Stimuvax will now be tested in two different cancer types in Phase III," said Dr Oliver Kisker, Senior Vice-President, Global Clinical Development Unit Oncology, Merck Serono. The Phase III program for Stimuvax was initiated following results from a randomized Phase IIb study* of 171 patients with inoperable stage IIIb NSCLC, in which Stimuvax showed a trend towards extending median overall survival from 13.3 months for patients receiving best supportive care (BSC) to 30.6 months for patients receiving Stimuvax plus BSC.2,3 Reported side effects included mild-to-moderate flu-like symptoms, gastrointestinal disturbances and mild injection-site reactions. A further long-term safety analysis in 16 patients receiving prolonged treatment with Stimuvax from 2.0 to 8.2 years showed the most common treatment-related adverse events were injection-site reactions (ISRs) with no evidence of autoimmune reactions. These data also show that the occurrence of ISRs decreased with long-term therapy (>1 year).4 Stimuvax was the first investigational cancer vaccine to enter Phase III clinical testing in NSCLC with the February 2007 launch of the START study, which will involve more than 1,300 patients with unresectable stage III NSCLC, who were stable or responding after chemoradiotherapy. Breast Cancer Facts - Worldwide, more than a million women are diagnosed with breast cancer every year, including 430,000 women in Europe and 212,920 in the U.S.5 - Breast cancer is the leading cause of cancer deaths in women worldwide, resulting in approximately 519,000 deaths per year, globally6 - Despite improved breast cancer survival rates, it is currently estimated that 28% of women diagnosed with invasive breast cancer in Europe and the U.S. will not live longer than 10 years7,8 - On average, 30% of patients with early-stage breast cancer suffer a recurrence and in most cases, the cancer will have spread beyond the breast9 - Approximately 70% of breast cancer patients are hormone receptor-positive and hormone therapy is a widely accepted treatment modality for these patients10 aSTRIDE: STimulating immune Response In aDvanced brEast cancer bSTART: Stimulating Targeted Antigenic Responses To NSCLC *The study was initially conducted by Oncothyreon Inc. The long-term follow-up was done by Merck Serono. References 1. Ho SB, et al. Cancer Res 1993;53(3):641-51. 2. Butts C, et al. J Clin Oncol 2005;23:6674-81. 3. Butts C, et al. J Thorac Oncol 2007;2(Suppl. 4):S332-3. Abstract No: B1-01. 4. Butts C, et al. ASCO Congress 2009; Abstract No: 3055. 5. Cancer Research UK. Breast cancer incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/breast/incidence. 6. World Health Organization. Factsheet No 297. http://www.who.int/mediacentre/factsheets/fs297/en/ 7. Peto R, et al. Lancet 2000;355:1822. 8. Cancer research UK. Predicted improvements in breast cancer survival. http://www.cancerhelp.org.uk/help/default.asp?page=15070. 9. Gonzalez-Angulo AM, et al. Adv Exp Med Biol 2007;608:1-22. 10. Anderson WF, et al. Breast Cancer Res Treat 2002;76:27-36. For more information on Stimuvax, please visit: http://www.globalcancernews.com. About Stimuvax Merck is investigating the use of Stimuvax® (BLP25 Liposome Vaccine) in the treatment of NSCLC. The vaccine was granted fast-track status in September 2004 by the FDA. Merck obtained the exclusive worldwide licensing rights from Oncothyreon Inc., Seattle, Washington, USA. Stimuvax is being developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc. START is a multi-center, randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study will involve more than 1,300 patients in approximately 30 countries. STRIDE is a randomized, double-blind, controlled, multi-center Phase III study designed to determine if Stimuvax® can extend progression free survival in patients treated with hormonal therapy who have inoperable, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study. Merck Serono Merck


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009